Expression of B Cell Translocation Gene 1 Protein in Colon Carcinoma and its Clinical Significance

Author(s): Junhe Zhang*, Weihua Dong

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 15 , Issue 1 , 2020

Become EABM
Become Reviewer

Abstract:

Background: Colon cancer is one of the most common malignant tumors, and B cell Translocation Gene (BTG)1 is involved in the occurrence and development of colon cancer, however, the underlying molecular mechanism remains unclear.

Objective: In this study, we investigated the expression of BTG1 protein in colon cancer, and its association with clinicopathology and prognosis.

Methods: The tumor specimens from 59 patients with colon cancer who had undergone radical colectomy were selected as the observation group. Para-carcinoma tissues from the same patients were selected as the control group. The expressions of BTG1 mRNA and protein in the specimen of two groups were analyzed by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and Western blot. According to the immunohistochemical results, the patients were divided into BTG1-negative and BTG1-positive groups. The postoperative cumulative survival rate in the two groups was analyzed. The association of the expression of BTG1 protein with the clinicopathological features and postoperative survival was investigated.

Results: Compared with the control group, the expression levels of BTG1 mRNA and BTG1 protein were significantly decreased in the observation group (P < 0.05). Immunohistochemical analysis revealed that there were 12 positive tumor samples and 47 negative samples. The expression of BTG1 was negatively associated with the degree of differentiation and lymphatic metastasis. The cumulative survival rate of BTG1-positive patients was significantly increased compared with that of BTG1- negative patients (P < 0.05). Stepwise Cox regression analysis showed that lymphatic metastasis, tumor size and BTG1 expression level were independent prognostic factors for overall survival in patients with colon cancer.

Conclusion: BTG1 protein in colon cancer tissues were expressed at low levels, which was associated with the clinicopathological features, postoperative recurrence and survival of patients.

Keywords: B Cell translocation gene 1, colon cancer, diagnosis marker, prognosis, recurrence rate, survival rate.

[1]
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62(1): 10-29.
[http://dx.doi.org/10.3322/caac.20138] [PMID: 22237781]
[2]
Jurjus A, Eid A, Al Kattar S, et al. Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links. BBA Clin 2015; 5: 16-24.
[http://dx.doi.org/10.1016/j.bbacli.2015.11.002] [PMID: 27051585]
[3]
O’Keefe SJ. Diet, microorganisms and their metabolites, and colon cancer. Nat Rev Gastroenterol Hepatol 2016; 13(12): 691-706.
[http://dx.doi.org/10.1038/nrgastro.2016.165] [PMID: 27848961]
[4]
Sergio B, Salvatore B, Francesca V. Method for preventing or reducing colon carcinogenesis or oxidative stress CN106955281. (2017).
[5]
Kim JH, Lee HK, Baek JH, Kwon KA. The method of prediction of carcinogenesis in colon cancer and prevention of colon cancer using altered expression in lipid metabolites KR20190021988. (2019).
[6]
Santarelli RL, Pierre F, Corpet DE. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr Cancer 2008; 60(2): 131-44.
[http://dx.doi.org/10.1080/01635580701684872] [PMID: 18444144]
[7]
Barry HC. Colorectal cancer screening modalities: Variable uptake, variable yield. Am Fam Physician 2016; 93(12): 1032-6.
[PMID: 27304774]
[8]
Yamada T, Fukuda S, Yachida S. Method for detecting early colon cancer WO2019151515. (2019).
[9]
Malhotra P, Anwar M, Nanda N, et al. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumour Biol 2013; 34(3): 1901-11.
[http://dx.doi.org/10.1007/s13277-013-0734-y] [PMID: 23526092]
[10]
Rui Y, Wang C, Zhou Z, Zhong X, Yu Y. K-Ras mutation and prognosis of colorectal cancer: a meta-analysis. Hepatogastroenterology 2015; 62(137): 19-24.
[PMID: 25911860]
[11]
Liu B, Yuan B, Zhang L, Mu W, Wang C. ROS/p38/p53/Puma signaling pathway is involved in emodin-induced apoptosis of human colorectal cancer cells. Int J Clin Exp Med 2015; 8(9): 15413-22.
[PMID: 26629030]
[12]
Guzińska-Ustymowicz K, Pryczynicz A, Kemona A, Czyzewska J. Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. Anticancer Res 2009; 29(8): 3049-52.
[PMID: 19661314]
[13]
Zhao S, Chen SR, Yang XF, et al. BTG1 might be employed as a biomarker for carcinogenesis and a target for gene therapy in colorectal cancers. Oncotarget 2017; 8(5): 7502-20.
[http://dx.doi.org/10.18632/oncotarget.10649] [PMID: 27447746]
[14]
Sun GG, Wang YD, Cheng YJ, Hu WN. The expression of BTG1 is downregulated in nasopharyngeal carcinoma and possibly associated with tumour metastasis. Mol Biol Rep 2014; 41(9): 5979-88.
[http://dx.doi.org/10.1007/s11033-014-3475-0] [PMID: 24985971]
[15]
Zhang H, Tang J, Li C, et al. MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. Cancer Lett 2015; 356(2 Pt B): 781-90.
[http://dx.doi.org/10.1016/j.canlet.2014.10.029] [PMID: 25449431]
[16]
Lundin C, Hjorth L, Behrendtz M, et al. High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome. Genes Chromosomes Cancer 2012; 51(2): 196-206.
[http://dx.doi.org/10.1002/gcc.20944] [PMID: 22072402]
[17]
Zhu MM. Novel function for upgrading Btg2 (B-cell translocation gene 2) expression level of genetic engineering mice CN106188272. (2016).
[18]
Fan SJ, Hu XD. Application of BTG2 (B Cell Translocation Gene 2) in preparing medicament for inhibiting cancer transfer CN102028956. (2011).
[19]
Kunsch C, Chopra A, Rosen C. Human B cell translocation gene-2 and 3 JP2002355080. (2002).
[20]
Chen Y, Wang C, Wu J, Li L. BTG/Tob family members Tob1 and Tob2 inhibit proliferation of mouse embryonic stem cells via Id3 mRNA degradation. Biochem Biophys Res Commun 2015; 462(3): 208-14.
[http://dx.doi.org/10.1016/j.bbrc.2015.04.117] [PMID: 25951976]
[21]
Wang Y, Sun W, Yang J, et al. PUM2 promotes glioblastoma cell proliferation and migration via repressing BTG1 expression. Cell Struct Funct 2019; 44(1): 29-39.
[http://dx.doi.org/10.1247/csf.18030] [PMID: 30787206]
[22]
Jiang R, Hu W, Sun G, Wang J, Han X. [Expression of BTG1 protein in laryngeal squamous cell carcinoma and its clinical significance]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2015; 29(16): 1447-50.
[PMID: 26665453]
[23]
Zheng HC, Li J, Shen DF, et al. BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy. Oncotarget 2015; 6(23): 19685-705.
[http://dx.doi.org/10.18632/oncotarget.4081] [PMID: 26050197]
[24]
Zhu R, Li W, Xu Y, Wan J, Zhang Z. Upregulation of BTG1 enhances the radiation sensitivity of human breast cancer in vitro and in vivo. Oncol Rep 2015; 34(6): 3017-24.
[http://dx.doi.org/10.3892/or.2015.4311] [PMID: 26503430]
[25]
Li J, Guo BC, Sun LR, et al. TNM staging of colorectal cancer should be reconsidered by T stage weighting. World J Gastroenterol 2014; 20(17): 5104-12.
[http://dx.doi.org/10.3748/wjg.v20.i17.5104] [PMID: 24803826]
[26]
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25(4): 402-8.
[http://dx.doi.org/10.1006/meth.2001.1262] [PMID: 11846609]
[27]
Zhou B, Wang G, Gao S, et al. Expression of GOLPH3 protein in colon cancer tissues and its association with the prognosis of patients. Oncol Lett 2016; 12(5): 3936-40.
[http://dx.doi.org/10.3892/ol.2016.5215] [PMID: 27895752]
[28]
Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987; 8(3): 138-40.
[PMID: 3303008]
[29]
Issa IA, Noureddine M. Colorectal cancer screening: An updated review of the available options. World J Gastroenterol 2017; 23(28): 5086-96.
[http://dx.doi.org/10.3748/wjg.v23.i28.5086] [PMID: 28811705]
[30]
Krebs B. Prebiotic and synbiotic treatment before colorectal surgery-randomised double blind trial. Coll Antropol 2016; 40(1): 35-40.
[PMID: 27301235]
[31]
Silva GL, de Moura EG, Bernardo WM, et al. Endoscopic versus surgical resection for early colorectal cancer-a systematic review and meta-analysis. J Gastrointest Oncol 2016; 7(3): 326-35.
[http://dx.doi.org/10.21037/jgo.2015.10.02] [PMID: 27284463]
[32]
Carini F, Mazzola M, Rappa F, et al. Colorectal carcinogenesis: Role of oxidative stress and antioxidants. Anticancer Res 2017; 37(9): 4759-66.
[PMID: 28870894]
[33]
Parsons BL, Myers MB, Meng F, Wang Y, McKinzie PB. Oncomutations as biomarkers of cancer risk. Environ Mol Mutagen 2010; 51(8-9): 836-50.
[http://dx.doi.org/10.1002/em.20600] [PMID: 20740637]
[34]
Hu RT, Chen JZ, Han Y, et al. Usage of IC53 gene and its related products for diagnosis and treatment of colon cancer and a kit for diagnosing colon cancer CN1556221. (2006).
[35]
Hou CM, Han GC, Chen GJ, et al. A colon cancer diagnosis kit based on DNAH5 gene CN104611446. (2016).
[36]
Stürzl M, Croner RS, Konrad A. Method for detecting an increased risk or incidence of colorectal cancer US2019169699. (2019).
[37]
Jenkins M, Buchanan D, Hopper JL. Methods for assessing risk of developing colorectal cancer US2019161802. (2019).
[38]
Xiao F, Deng J, Yu J, Guo Y, Chen S, Guo F. A novel function of B-cell translocation gene 1 (BTG1) in the regulation of hepatic insulin sensitivity in mice via c-Jun. FASEB J 2016; 30(1): 348-59.
[http://dx.doi.org/10.1096/fj.15-278689] [PMID: 26396236]
[39]
Liu C, Tao T, Xu B, et al. BTG1 potentiates apoptosis and suppresses proliferation in renal cell carcinoma by interacting with PRMT1. Oncol Lett 2015; 10(2): 619-24.
[http://dx.doi.org/10.3892/ol.2015.3293] [PMID: 26622543]
[40]
Qian Y, Lu X, Li Q, Zhao S, Fang D. The treatment effects and the underlying mechanism of B cell translocation gene 1 on the oncogenesis of brain glioma. J Cell Biochem 2019; 120(8): 13310-20.
[http://dx.doi.org/10.1002/jcb.28605] [PMID: 30916818]
[41]
Zhu R, Zou ST, Wan JM, Li W, Li XL, Zhu W. BTG1 inhibits breast cancer cell growth through induction of cell cycle arrest and apoptosis. Oncol Rep 2013; 30(5): 2137-44.
[http://dx.doi.org/10.3892/or.2013.2697] [PMID: 23982470]
[42]
Sun GG, Lu YF, Cheng YJ, Hu WN. The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis. Tumour Biol 2014; 35(12): 11771-9.
[http://dx.doi.org/10.1007/s13277-014-2298-x] [PMID: 25173640]
[43]
Xie J, Wang Q, Wang Q, et al. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia. Cancer Genet 2014; 207(5): 226-30.
[http://dx.doi.org/10.1016/j.cancergen.2014.05.003] [PMID: 24998463]
[44]
Jung YY, Sung JY, Kim JY, Kim HS. Down-regulation of B-cell translocation gene 1 by promoter methylation in colorectal carcinoma. Anticancer Res 2018; 38(2): 691-7.
[PMID: 29374692]
[45]
Su C, Huang DP, Liu JW, Liu WY, Cao YO. miR-27a-3p/BTG1 axis may have potential implications for diagnostic and therapeutic approaches. Oncol Lett 2019; 18(3): 2825-34.
[PMID: 31452761]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2020
Page: [78 - 85]
Pages: 8
DOI: 10.2174/1574892815666200109113114
Price: $65

Article Metrics

PDF: 12
HTML: 2
EPUB: 1
PRC: 1